EnviroTech :: Regulatory
Lonza and Biotech Firm Settle Legal Dispute
11:43 AM MDT | May 6, 2008 | DR
Lonza (Basel, Switzerland) says it has settled a legal dispute with biotechnology company Northwest Biotherapeutics (Bethesda, MD) involving Lonza’s GS Gene Expression System. All claims and counterclaims between the companies are to be dismissed, based on an agreement that Northwest Biotherapeutics will destroy the GS Gene Expression System materials in its possession, Lonza says. The GS Gene Expression System, which is owned and licensed by Lonza, is used to produce therapeutic recombinant proteins and monoclonal antibodies. This system is characterized...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee